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Oseltamivir-
Resistant Pandemic 
(H1N1) 2009 in 
Patient with 
Impaired Immune 
System
To the Editor: We detail the de-
velopment of oseltamivir-resistant 
pandemic (H1N1) 2009 in a chroni-
cally immunocompromised patient 
and the pitfalls encountered when 
treating such patients with neuramin-
idase inhibitors. On August 6, 2009, 
a 56-year-old man was seen in the 
emergency room of a local hospital 
with a 24-hour history of fever, my-
algia, coryzal symptoms, and cough. 
He was on day 3 of a postexposure 
course of oseltamivir (75 mg 1×/d); 
inﬂ  uenza A had been presumptively 
diagnosed for his wife after she had 
similar symptoms.
The patient’s medical history 
showed grade IVB nodular sclerosing 
Hodgkin lymphoma, which had been 
diagnosed in 2001. Lymphoma was 
initially treated with chemotherapy, 
but relapse required autologous pe-
ripheral stem cell transplantation in 
July 2005. Further relapses in 2006 
and 2007 were treated with radiother-
apy and chemotherapy, respectively, 
before the patient underwent an allo-
geneic peripheral stem cell transplan-
tation in July 2008. This treatment was 
complicated by graft-versus-host dis-
ease, and the patient required ongoing 
immunosuppression.
When hospitalized, the patient 
was being treated with cyclosporine 
A (50 mg/d) and prednisolone (20 
mg/d). Physical examination showed 
a temperature of 39°C and wheezing 
from the left lung. Initial tests showed 
a neutrophil count of 2.02 × 109/L, 
a lymphocyte count of 0.87 × 109/L, 
and a C-reactive protein level of 33 
mg/L. He was started on piperacillin–
tazobactam and gentamicin, and osel-
tamivir was increased to the treatment 
dose of 75 mg 2×/d. A nasopharyngeal 
aspirate collected on August 7 con-
tained pandemic (H1N1) 2009 viral 
RNA by real-time PCR for generic in-
ﬂ  uenza A (1) and capillary sequencing 
for subtype H1N1 (testing by Micro-
pathology Ltd, Coventry, UK). By Au-
gust 9, the patient was still febrile, and 
zanamivir (10 mg 2×/d) was started. 
Oseltamivir was given for a total of 7 
d and zanamivir for 3 d.
Nose and throat swabs taken on 
August 21 still contained pandemic 
(H1N1) 2009 viral RNA. Real-time 
PCR and pyrosequencing demonstrat-
ed a histidine-to-tyrosine substitution 
(H275Y) in the neuraminidase gene 
associated with oseltamivir resistance 
(Respiratory Virus Unit, Centre for 
Infections, Health Protection Agen-
cy; methods not in public domain). 
A mixture of wild-type and resistant 
virus was present (A. Lackenby, pers. 
comm.). The sample from August 7 
did not contain this mutation, suggest-
ing a de novo H275Y substitution sec-
ondary to oseltamivir use.
The patient improved and was 
discharged on August 23 but returned 
for treatment on September 7 with 
worsening fever and cough. Nose and 
throat swabs obtained on September 
11 were PCR negative, but follow-up 
samples on September 25 and Octo-
ber 1 contained detectable pandemic 
(H1N1) 2009 viral RNA. Because vi-
rus isolation was not performed, true 
infectivity remains unresolved, but in-
termittent detection suggests ongoing 
replication, such as that seen in other 
immunocompromised patients (2,3).
By February 3, 2010, a total of 
225 cases of oseltamivir-resistant pan-
demic (H1N1) 2009 had been identi-
ﬁ  ed worldwide; a high proportion of 
cases were in immunocompromised 
persons (4). A minority of these muta-
tions were detected in treatment-naive 
patients. Immunocompromised, par-
ticularly lymphopenic, patients shed 
virus for prolonged periods leading 
to longer treatment courses and viral 
shedding reviving on termination of 
treatment. Viral shedding for up to 
18 months has been reported for sea-
sonal inﬂ  uenza, which has important 
implications for infection control (5). 
Our patient demonstrated that a single 
PCR-negative test does not reliably 
determine the end of viral shedding, 
which continued despite co-treatment 
with 2 neuraminidase inhibitors. 
Neuraminidase inhibitors interfere 
with the release of progeny inﬂ  uenza 
virus from their infected host cells. Ef-
fective treatment depends partially on 
immune system destruction of the foci 
of infection (6), or potential persis-
tent viral particles can be released as 
soon as oseltamivir therapy is stopped. 
The low genetic barrier to oseltamivir 
means that resistance is a likely con-
sequence of monotherapy in immuno-
compromised patients.
Concern about oseltamivir resis-
tance has led to issuance of additional 
guidelines, especially in light of the 
transmission of resistant virus between 
immunocompromised patients on hos-
pital wards in the United States and 
Wales (7,8). This ﬁ  nding suggests that 
immunocompromised patients should 
be treated with oseltamivir and zana-
mivir, or with zanamivir alone, for a 
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minimum of 10 d. Patients should be 
retested for ongoing viral secretion ev-
ery 5 d and negative results conﬁ  rmed 
with a follow-up sample after 48 h. 
Classic virus isolation in addition to 
molecular methods may also identify 
potentially infectious patients.
Prophylactic neuraminidase in-
hibitor use in such patients also needs 
to be addressed. Resistance is more 
likely with the reduced prophylactic 
dose of oseltamivir and is more likely 
to be a problem in immunocompro-
mised patients. Zanamivir is now the 
drug of choice for prophylaxis for 
such patients, although some experts 
propose no prophylaxis and instead 
early treatment after symptom onset 
(9).
Immunocompromised patients 
are more likely to shed virus for pro-
longed periods and are more likely to 
develop oseltamivir-resistance, espe-
cially when this drug is used as mono-
therapy. Further clinical experience 
and trials will support or refute newer 
guidelines on the management of pan-
demic (H1N1) 2009 in such patients.
Funding for this investigation and pa-
tient care was obtained under state-funded 
medical care provisions.
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Sapovirus in Adults 
in Rehabilitation 
Center, Upper 
Austria
To the Editor: Contrary to no-
rovirus (NoV) infections, sapovirus 
(SaV) is believed to affect mainly 
young children (1), although recent 
studies show that SaV is present in all 
age groups (2,3). SaV has been clas-
siﬁ   ed into 5 genogroups, of which 
GI, GII, GIV, and GV affect humans 
(4). SaV can be transmitted in vari-
ous ways, including person-to-person 
fecal–oral route, by aerosol, and by 
consumption of contaminated food or 
water (5). Outbreaks of SaV have been 
reported in various settings but are less 
common than NoV outbreaks (1,6).
During October 2–7, 2008, an 
outbreak of gastroenteritis occurred 
in a rehabilitation center in Upper 
Austria. Signs including diarrhea, 
vomiting, and fever developed in 21 
adult patients and 12 staff members. 
The observed signs and the likely 
incubation period initially suggested 
NoV as the cause of the outbreak. 
Stool specimens of 10 patients were 
collected and submitted to the Insti-
tute for Medical Microbiology and 
Hygiene in Graz.
Along with microbiologic inves-
tigations, infection control measures 
were introduced by local authorities 
on each affected ward. The earliest re-
ported onset of illness was on October 
2, 2008, in a 52-year-old woman on the 
third ﬂ  oor. The next day 2 additional 
patients on the same ﬂ  oor and 1 mem-
ber of the kitchen staff showed symp-
toms. Another 7 patients, on 3 differ-
ent ﬂ  oors, and 2 of the medical staff 
suffered from symptoms the following 
day (October 4). The outbreak peaked 
with 11 cases 3 days after the initial 
episode of vomiting. An additional 9 
persons became infected (5 patients, 
a doctor, janitor, psychotherapist, and 
kitchen worker) within the following 
2 days. The affected patients were pre-
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